Browse > Article

The Activation of HCV-specific CD8 T Cells by HCV Peptide Pulsed Huh7.5 Cells  

Cho, Hyo-Sun (Department of Pharmacy, Duksung Women's University)
Publication Information
Korean Journal of Microbiology / v.47, no.4, 2011 , pp. 342-347 More about this Journal
Abstract
T cells play a key role in viral infection. However, in patients with chronic hepatitis C virus (HCV) infection, HCV-specific T cells are dysfunctional and impaired in the liver, which is the primary site for HCV replication. There are multiple potential mechanisms for HCV-specific T cell dysfunction including induction of immune inhibitory pathways (program death-1; PD-1, cytotoxic t lymphocyte associated antigen-4; CTLA-4) and immune tolerance induced specific for the liver. However, the interaction between hepatocytes and HCV-specific CD8 T cells has not clearly established. In this study, we confirmed huh (human hepatoma) 7.5 cells expressing HLA (human leukocyte antigen) A2 presented antigen to activate HCV-specific CD8 T cells in HLA A2-restricted manner and expression of PD-L (program death ligand) 1 on huh7.5 cells reduced HCV-specific CD8 T cell activation, suggesting an immune modulatory activity. Loss of HCV-specific tetramer responses following antigenic stimulation correlated with increased caspase-3 activity. In addition, PD-L1 on huh7.5 cells rescued HCV-specific CD8 T cells from apoptosis. Our results suggest that the interaction between PD-L1 and PD-1 can recover the function of HCV-specific CD8 T cells in the liver, which could be applied in therapy of HCV chronic infection.
Keywords
hepatitis C virus (HCV); HCV-specific T cells; hepatoma cell line 7.5 (huh7.5); PD-L1;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Freeman, G.J., A.J. Long, and Y. Iwai. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034.   DOI   ScienceOn
2 Freeman, G.J., E.J. Wherry, R. Ahmed, and A.H. Sharpe. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203, 2223-2227.   DOI   ScienceOn
3 Golden-Mason, L., B. Palmer, J. Klarquist, J.A. Mengshol, and N. Castelblanco. 2007. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81, 9249-9258.   DOI   ScienceOn
4 Lauer, G.M. and B.D. Walker. 2001. Hepatitis C virus infection. New Engl. J. Med. 345, 41-52.   DOI   ScienceOn
5 Greenwald, R.J., G.J. Freeman, and A.H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23, 515-548.   DOI   ScienceOn
6 Holz, L.E., A. Warren, D.G. Le Couteur, D.G. Bowen, and P. Bertolino. 2010. CD8+ T cell tolerance following antigen recognition on hepatocytes. J. Autoimmun. 34, 15-22.   DOI   ScienceOn
7 Jo, J., U. Aichele, N. Kersting, R. Klein, P. Aichele, E. Bisse, A.K. Sewell, H.E. Blum, R. Bartenschlager, V. Lohmann, and R. Thimme. 2009. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 136, 1391-1401.   DOI   ScienceOn
8 Jo, J., V. Lohmann, R. Bartenschlager, and R. Thimme. 2011. Experimental models to study the immunobiology of hepatitis C virus. J. Gen. Virol. 92, 477-493.   DOI   ScienceOn
9 Keril, J.B., A.J. McKeating, and M.C. Rice, 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76, 13001-13014.   DOI   ScienceOn
10 Nakamoto, N., D.E. Kaplan, J. Coleclough, Y. Li, M.E. Valiga, and K.M. Chang. 2008. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134, 1927-1937.   DOI   ScienceOn
11 Uebelhoer, L., J.H. Han, B. Callendret, G. Mateu, N.H. Shoukry, H.L. Hanson, C.M. Rice, C.M. Walker, and A. Grakoui. 2008. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 4, e1000143.   DOI
12 Nakamoto, N., H. Cho, A. Shaked, K. Olthoff, M.E. Valiga, M. Kaminski, E. Gostick, D.A. Price, G.J. Freeman, E.J. Wherry, and K.M. Chang. 2009. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313.   DOI   ScienceOn
13 Pagliaro, L., A. Craxi, C. Cammaa, F. Tine, V. di Marco, L. Iacono, and P. Almasio. 1994. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 19, 820-828.
14 Salomon, B. and J.A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252.   DOI   ScienceOn
15 Chayama, K., C.N. Hayes, N. Hiraga, H. Abe, M. Tsuge, and M. Imamura. 2011. Animal model for study of human hepatitis viruses. J. Gastroenterol. Hepatol. 26, 13-18.   DOI   ScienceOn
16 Varela-Rohena, A., C. Carpenito, E.E. Perez, M. Richardson, R.V. Parry, M. Milone, J. Scholler, X. Hao, A. Mexas, R.G. Carroll, C.H. June, and J.L. Riley. 2008. Genetic engineering of T cells for adoptive immunotherapy. Immunol. Res. 42, 166-181.   DOI   ScienceOn
17 Wherry, E.J. and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 8, 5535-5545.
18 Willberg, C., E. Barnes, and P. Klenerman. 2003. HCV immunology-death and the maiden T cell. Cell. Death Differ. 10, S39-47.   DOI   ScienceOn
19 Bertolino, P., G.W. McCaughan, and D.G. Bowen. 2002. Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol. Cell. Biol. 80, 84-92.   DOI   ScienceOn
20 Binder, M., G. Kochs, R. Bartenschlager, and V. Lohmann. 2007. Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 46, 1365-1374.   DOI   ScienceOn